A pilot study evaluating the treatment of postparotidectomy sialoceles with botulinum toxin type A.
To report our experience in treating 4 cases of recurrent siacloceles with botulinum toxin type A after partoid surgery. This is a prospective, nonrandomized, nonblinded pilot study describing a new use for botulinum toxin type A. Tertiary academic medical center. Four patients (2 men and 2 women) with persistent postparotidectomy sialoceles who had undergone various treatment failures were included. The diagnosis was made by fine-needle aspiration of the mass based on well-recognized cytologic features of the entity, as well as an elevated amylase level and no evidence of tumor or infection. Sialoceles were aspirated before local injection of botulinum toxin type A (30-50 U) subcutaneously. The patients were followed up 1 week after receiving botulinum toxin type A injection and then at monthly intervals. They were extensively questioned and examined for any evidence of side effects or recurrence. All patients had total resolution of sialocele or external salivary fistula within 1 month of treatment. None of the patients to date have demonstrated recurrences at 7 through 13 months, and there were no complications, particularly facial nerve weakness. Our findings suggested that botulinum toxin type A offers a highly effective, safe, and noninvasive method of treatment in postparotidectomy sialocele.